kol takeaway pain reduct import consider
surpris renevia approv could lead partner eu asia
south america
lenti-d continu shine starbeam
meet manag highlight upsid
miss fshd look toward lu mf data ye
analyst certif import disclosur see
top stori week hous democrat releas version drug price bill would allow govern
negoti price medicar biggest-ticket item plan put floor vote later year need
proceed committe noth confirm schedul quit full fall subsequ presid issu
support legisl call bi-partisan deal howev progress continu speak bill
narrow conserv continu oppos price restrict
enter stretch run sens ennui among generalist specialist biotech investor
sector continu under-perform versu broader market ytd basi see exhibit
reason under-perform mani vari detect three broad theme convers
investor manag potent sales/earn deceler among large-cap biotech compani start
concern regard impend drug price legisl continu rhetor issu
presidenti elect year pauciti excit pipelin project mirror groundbreak therapi launch
expect strong sales/earn season strong nov-feb period biotech stock
perform break trend would posit environ favor snss
arql
kol takeaway pain reduct import consider select patient bill barrier come
recent met dr abhishek chatterje chief surgeri tuft medic center kol level trauma
center use skint product ten patient import takeaway includ new price model skint
improv eas receiv payment signific barrier order regularli wound
target opportun fo skint experi trauma chronic wound posit
nine ten case experienc full closur tenth case larg wound approach report durabl partial
closur interestingli cite earli reduct pain relat control inflamm import improv patient
qualiti life
time road manag highlight current new revenu driver us new patient
growth largest driver strong perform ytd led basal-iq launch look forward
two signific product launch track next month slim control-iq hybrid close loop
sport half size slim expect smartphon control anima convers wane expect
compani highlight numer new growth opportun includ new product rollout acceler market growth
long runway ahead new countri target increasingli materi renew revenu believ build renew
opportun under-appreci driver reiter outperform
surpris renevia approv could lead partner eu asia south america
announc renevia receiv ce mark europ treatment facial fat loss given long regulatori
review nearli month remov renevia forecast takeaway includ announc repres
upsid outlook expect seek partner product outsid us up-front econom could
provid need balanc sheet flexibl continu believ addit studi necessari receiv fda approv
last look present opregen data american associ ophthalmolog confer
octob next catalyst
lenti-d continu shine starbeam
wednesday epn congress bluebird present updat result on-going starbeam trial
investig lenti-d cerebr adrenoleukodystrophi cald updat includ fresh data fully-enrol
patient trial median follow-up time month major function disabl mfd -free surviv remain
patient least month follow-up higher patient month follow-up view latest
data continu showcas lenti-d safer altern allogen stem cell transplant allo-hsct de facto standard
care given rariti cald see larg commerci opportun lenti-d view program import
proof-of-concept bluebird gene therapi platform rare diseas reiter perform
time road manag highlight near long-term revenu driver integr
codman larg behind compani manag turn focu toward addit growth initi led new product
flow tuck-in invest lead way highlight sever long-term product opportun includ
recent announc acquisit rebound therapeut mi neurosurg procedur on-going develop
short-stem stemless shoulder see opportun intern expans particularli japan benefit
regen manufactur capac invest solid product flow neuro cerelink icp monitor certa
drainag valv target organ sale growth next year manag also highlight sever driver
drive convers gm expans
meet manag highlight upsid
attend meet addu manag team includ ceo dirk allison cfo brian poff believ
opportun remain highli promis organ trend remain strong new york narrow network still drive
mid-to-high teen growth market annual octob meanwhil compani robust pipelin continu
catalyst go forward although top-lin trend remain highli promis margin remain much potenti driver
manag continu expect ebitda margin approach owe upsid margin
rais ep estim reflect recent secondari offer close
hpa deal estim accret
miss fshd look toward lu mf data ye
decis discontinu develop facioscapulohumer muscular dystrophi fshd follow
failur show function improv remov potenti pipelin opportun program contribut
valuat poc data charcot-marie-tooth cmt remain track nearer term look forward top-lin
data luspatercept phase trial myelofibrosi mf would expect posit readout yield upsid
share given believ balanc expect kol spoken express cautiou optim
decreas pt lower pipelin valu reiter outperform
last week democrat presidenti candid debat saw former vice presid biden pitch public option
critic medicar senat warren sander argu favor help mayo
clinic store/analyz health/financi data though hospit cloud migrat slow unwilling write server
invest even replac secur cost drive cloud shift wsj
sept fall summit focus specialti pharma diseas compani new york citi -- start next monday
oct houston oncolog summit md anderson cancer center
healthcar provid manag
